Logo

OncoDNA: Bernard Courtieu, Jean-Pol Detiffe, Eduardo Bravo

Jan 25, 2021

OncoDNA has appointed Bernard Courtieu as CEO and Jean-Pol Detiffe as chief strategic and innovation officer. Courtieu previously served as CEO of IntegraGen, which was acquired by OncoDNA last July. Prior to IntegraGen, Courtieu served as VP at Gemini Consulting.

Eduardo Bravo, who currently serves as interim CEO of OncoDNA, will remain a consultant to the firm's board. 

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.